Bill Doyle

Executive Chairman

Novocure GmbH

Since 2004, Bill has served as Executive Chairman of Novocure GmbH (NVCR). Novocure is pioneering Tumor Treating Fields, a new therapeutic modality for solid tumors. Tumor Treating Fields target the electrical properties of cells rather than their chemical properties to selectively kill cancer cells and extend patient survival. Novocure conducted the only successful phase 3 trial in 23 years treating GBM brain cancer and has treated ~30,000 GBM patients in the commercial setting.

Recently Novocure announced the success of the LUNAR phase 3 trial in metastatic non-small cell lung cancer (NSCLC). LUNAR met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival when TTFields was added to standard chemotherapy or immunotherapy compared to standard chemotherapy or immunotherapy alone. This is the first progress for this group of patients in seven years.

Previously, as an executive of Johnson & Johnson, Bill was a member of J&J’s Consumer Pharmaceuticals and Medical Devices Group Operating Committee with responsibility for licensing, acquisitions & strategy. Bill was Chairman of J&J’s Medical Devices Research and Development Council, Worldwide President of Biosense-Webster, and a member of the internal boards of directors of Cordis Corporation and Johnson & Johnson Development Corporation (J&J's private equity subsidiary).

Bill received an SB in Materials Science and Engineering from MIT and an MBA from Harvard Business School. Bill serves on Harvard Business School’s Board of Dean’s Advisors, Harvard Business School’s Healthcare Advisory Board, MIT’s Institute of Medical Engineering & Science (IMES) Visiting Committee.